Trexquant Investment LP Purchases 508,362 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Trexquant Investment LP grew its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 867.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 566,945 shares of the company’s stock after purchasing an additional 508,362 shares during the period. Trexquant Investment LP owned about 0.73% of Kura Oncology worth $4,938,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in KURA. Harbor Advisors LLC bought a new position in Kura Oncology in the 4th quarter valued at about $87,000. E Fund Management Co. Ltd. bought a new position in shares of Kura Oncology in the 4th quarter valued at $90,000. Corient Private Wealth LLC acquired a new position in shares of Kura Oncology during the 4th quarter worth $109,000. Teacher Retirement System of Texas lifted its position in shares of Kura Oncology by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock worth $120,000 after buying an additional 2,285 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in Kura Oncology in the fourth quarter valued at about $127,000.

Kura Oncology Stock Down 4.5 %

NASDAQ:KURA opened at $5.89 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market cap of $475.65 million, a P/E ratio of -2.50 and a beta of 0.83. Kura Oncology, Inc. has a fifty-two week low of $5.82 and a fifty-two week high of $23.48. The firm has a 50-day simple moving average of $7.68 and a two-hundred day simple moving average of $11.51.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. Analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on KURA shares. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. JMP Securities reissued a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research note on Thursday, February 27th. Finally, Scotiabank decreased their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.50.

Insiders Place Their Bets

In other news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is owned by insiders.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.